E
Agenus Inc. AGEN
$1.86 $0.18511.05%
Recommendation
Sell
Prev Close
$1.68
Volume
940,421
Avg Vol (90D)
492,828
Market Cap
$39.29M
Dividend & Yield
--
52-Week Range
$1.67 - $19.69
P/E (TTM)
--
EPS (TTM)
-$11.13
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Robert W. Baird Cuts Agenus (NASDAQ:AGEN) Price Target to $3.00
3/13/2025 - MarketBeat
Agenus (NASDAQ:AGEN) Given "Neutral" Rating at HC Wainwright
3/13/2025 - MarketBeat
Agenus Inc. Earnings Call: Mixed Sentiments and Strategic Focus
3/13/2025 - TipRanks Financial Blog
Agenus (NASDAQ:AGEN) Releases Earnings Results, Beats Estimates By $0.32 EPS
3/12/2025 - MarketBeat
Agenus price target lowered by $3 at Baird, here's why
3/12/2025 - The Fly
Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges
3/12/2025 - GuruFocus
Q4 2024 Agenus Inc Earnings Call Transcript
3/12/2025 - GuruFocus
Agenus Inc. Reports Strategic Cost Reductions and BOT/BAL Progress
3/12/2025 - TipRanks Financial Blog
Agenus (AGEN) Q4 2024 Earnings Call Transcript
3/11/2025 - Fool.com Headlines
Agenus stock falls after revenue miss
3/11/2025 - Seeking Alpha - Healthcare
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
3/11/2025 - Seeking Alpha: Transcripts
Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript
3/11/2025 - SeekingAlpha
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
3/11/2025 - Zacks Investment Research
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant ...
3/11/2025 - GuruFocus
Agenus reports Q4 EPS ($2.04), consensus ($2.54)
3/11/2025 - The Fly
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
3/11/2025 - Business Wire
Agenus Q4 2024 Earnings Preview
3/10/2025 - SeekingAlpha.com: All News
Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Hold" by Brokerages
3/1/2025 - MarketBeat
AgenusReports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
2/26/2025 - Business Wire
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor ...
2/25/2025 - GuruFocus
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
2/25/2025 - Business Wire
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2/25/2025 - GuruFocus
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
2/25/2025 - Business Wire
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
2/24/2025 - GuruFocus
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
2/24/2025 - Business Wire
Income Statement
Total Revenue (TTM)
$160.43M
EBITDA (TTM)
-$85.52M
EBIT (TTM)
-$100.80M
Net Income (TTM)
-$227.64M
Balance Sheet
Total Assets (Q)
$238.48M
Total Debt (Q)
$78.87M
Total Liabilities (Q)
$510.29M
Book Value Per Share (Q)
-$13.48
Cash Flow
Cash from Operations (TTM)
-$170.07M
Cash from Investing (TTM)
$2.87M
Cash from Financing (TTM)
$105.79M
Net Change in Cash (TTM)
-$61.56M
Filings
Filing Date
Tuesday, November 12, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 10 and 14 (est)
Price History
Loading...
Beta
2.29
7-Day Total Return
-22.82%
30-Day Total Return
-47.46%
60-Day Total Return
-39.02%
90-Day Total Return
-55.71%
Year to Date Total Return
-39.81%
1-Year Total Return
-84.49%
2-Year Total Return
-94.71%
3-Year Total Return
-96.38%
5-Year Total Return
-95.75%
52-week Low
Mar 13, 2025 - $1.67
52-week High
Jun 04, 2024 - $19.69
Valuation
Market Cap
$39.29M - Nano Cap
Enterprise Value
$93.91M
Price/Sales (TTM)
0.23
Price/Book (Q)
-0.12
Dividends and Shares
Shares Outstanding
21.55M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.agenusbio.com
Phone Number
781 674 4400
Address
3 Forbes Road
Lexington, MA 02421-7305
Country
United States
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings